LUMIZYME Drug Profile

Summary for Tradename: LUMIZYME

High Confidence Patents:	9
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for LUMIZYME
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LUMIZYME

Recent Clinical Trials for LUMIZYME

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Valerion Therapeutics, LLC	Phase 1/Phase 2
Sanofi	Phase 3
Genzyme, a Sanofi Company	Phase 4

See all LUMIZYME clinical trials

Recent Litigation for LUMIZYME

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
LIQUIDIA TECHNOLOGIES, INC. v. UNITED THERAPEUTICS CORPORATION	2025-04-21

See all LUMIZYME litigation

Pharmacology for LUMIZYME

Established Pharmacologic Class	Hydrolytic Lysosomal Glycogen-specific Enzyme
Chemical Structure	alpha-Glucosidases

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for LUMIZYME Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for LUMIZYME Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	⤷ Start Trial	2036-12-20	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	⤷ Start Trial	2038-12-19	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	⤷ Start Trial	2034-05-02	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	⤷ Start Trial	2038-07-09	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	⤷ Start Trial	2038-09-17	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	⤷ Start Trial	2035-12-07	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	⤷ Start Trial	2021-07-10	DrugPatentWatch analysis and company disclosures
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Patent No.	>Estimated Patent Expiration	>Source

3) Low Certainty: US Patents for LUMIZYME Derived from Patent Text Search

These patents were obtained by searching patent claims